Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma

Bone Marrow Transplantation

Volumn 42, Issue 6, 2008, Pages 385-391

  Lee, S H ^a   Yoo, K H ^b   Sung, K W ^b   Kim, J Y ^b   Cho, E J ^b   Koo, H H ^b   Chung, S E ^b   Kang, S W ^b   Oh, S Y ^b   Ham, D I ^b   Kim, Y D ^b  

^a National Cancer Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; THIOTEPA; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFANT; INFECTION; LIVER TOXICITY; LOCAL THERAPY; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; SECOND CANCER; TREATMENT INDICATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETINOBLASTOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 53149125658     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.181     Document Type: Article

References (26)

1. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988; 95 1583-1587.
2. Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 2005; 23: 2272-2279.
3. Shields CL, Honavar SG,Meadows AT, Shields JA, Demirici H, Singh A et al. Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002; 133: 657-664.
4. Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18: 12-17.
5. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000; 18: 2881-2887.
6. Lee V, Hungerford JL, Bunce C, Ahmed F, Kingston JE, Plowman PN. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol 2003; 87: 1374-1380.
7. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006; 24: 2891-2896.
8. Sung KW, Yoo KH, Cho EJ, Koo HH, Lim do H, Shin HJ et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007; 48 408-415.
9. Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant 2007; 40: 37-45.
10. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II Study. J Clin Oncol 2002; 20: 2284-2292.
11. Shields JA, Shields CL. Atlas of Intraocular Tumors. Lippincott Williams & Wilkins: Philadelphia, PA, 1999, pp 207-232.
12. Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999; 36: 8-18.
13. Namouni F, Doz F, Tanguy ML, Quintana E, Michon J, Pacquement H et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: A SFOP and SFGM study. Eur J Cancer 1997; 33: 2368-2375.
14. Dunkel IJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV et al. Successful treatment of metastatic retinoblastoma. Cancer 2000; 89: 2117-2221.
15. Kremens B, Wieland R, Reinhard H, Neubert D, Beck JD, Klingebiel T et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 2003; 31 281-284.
16. Matsubara H, Makimoto A, Higa T, Kawamoto H, Skiyama S, Hosono A et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 2005; 35: 763-766.
17. Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Chemoreduction for retinoblastoma: Analysis of tumor control and risks for recurrence in 457 tumors. Trans Am Ophthalmol Soc 2004; 02 35-45.
18. Gündüz K, Günalp I, Yalçindad N, Unal E, Taçyildiz N, Erden E et al. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology 2004; 111: 1917-1924.
19. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol 2004; 122: 1316-1323.
20. Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH. Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 1998; 116: 887-893.
21. Demirci H, Eagle Jr RC, Shields CL, Shields JA. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol 2003; 121: 1125-1131.
22. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473-1478.
23. Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: A study of 341 patients. Ann Oncol 2004; 15: 1222-1230.
24. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J et al. econdary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440-3446.
25. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386-3391.
26. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.